Lantibiotics, ribosomally synthesized polycyclic peptide antibiotics, are produced by a variety of bacterial species. The nucleotide sequences of a number of the type A or linear lantibiotics have been reported in recent years (1, 2, 6-9, 11, 13, 14) , including the sequence of streptococcin A-FF22 (scnA), a lantibiotic from group A streptococci (5) . The deduced amino acid sequence of ScnA (previously referred to as SA-FF22) differed from other type A lantibiotics, particularly at the leader peptide cleavage site, suggesting some divergence of the peptidase or other gene product(s) involved in maturation (5) . Subsequently, two other lantibiotics, salivaricin A (11) and lacticin 481 (9) , have been reported to show variation from the typical cleavage site. Lacticin 481 and streptococcin A-FF22 share a high degree of amino acid similarity, and it was suggested these two lantibiotics may be members of a new class of type A lantibiotic (9) .
Tagg and Skjold (15) previously reported that 28% (21 of 75) of Streptococcus pyogenes strains of M-type 49 tested produced an inhibitory activity indistinguishable from that attributed to ScnA. These strains were from different phage subtypes and were isolated from various geographical regions. Streptococcin A-M49, as this inhibitory agent was named, was produced only when strains were incubated under anaerobic conditions. In the present study, we examined the relationship between ScnA and streptococcin A-M49 and describe the cloning and sequencing of the region encoding the structural genes of streptococcin A-M49 from strain GT9538.
Twenty-one M-type 49 group A streptococcal strains obtained from different geographical locations and isolated from patients with a variety of diseases (some strains were tested previously) were screened by the deferred antagonism method for production of streptococcin A-M49 (15) . Of the 21 strains tested, 7 strains (33%) produced an inhibitory activity, after anaerobic incubation, indistinguishable from that of strain FF22. In accordance with the results of a previous survey (15), none of the M-type 49 strains tested in the current study produced an ScnA-like inhibitory pattern following aerobic incubation. Strains were also examined by the PCR technique with crude cell lysates as previously described (4) . Oligonucleotide primers derived from the nucleotide sequence encompassing the scnA gene (5) prepared by the Molecular Biology Resource Facility of the Oklahoma Center for Molecular Medicine, Oklahoma City, Okla. Following PCR, strains which produced streptococcin A-M49 inhibitory activity gave a single amplified band, approximately 175 bp larger than the ScnA-associated fragment amplified from strain FF22. Strains which did not produce inhibitory activity did not amplify a DNA fragment (Fig. 1) .
Total cellular DNA from strain FF22 (scnA-containing strain [5] ), strain GT8760 (an M-type 49 strain which does not produce inhibitory activity [15]), and strains GT9538 and GT9653 (which produce streptococcin A-M49 inhibitory activity [15]) was prepared as previously described (3). The DNA was digested and used in Southern blot analysis with the 2.8-kb fragment containing the senA gene (5) as a probe. DNA probes were labeled with [32P]dATP by nick translation (12) . The probe hybridized to DNA fragments from strains FF22, GT9538, and GT9653, whereas no hybridization was observed with DNA from strain GT8760. A 3.5-kb EcoRI fragment from strain GT9538 which hybridized to the scnA probe was isolated and cloned into pGEM7Z(f-) (Promega Corporation) by established procedures. Clones were examined by colony blotting (3) with the scnA probe. Plasmid DNAs from positive clones were confirmed to contain the region of interest by PCR (4) and Southern blot analysis (12) . With the same primers as described above, a single band was amplified from the cloned DNA fragment. As observed following amplification of the streptococcal crude cell lysate, the amplified fragment was approximately 175 bp larger than that obtained following amplification of DNA from strain FF22. The 600-bp amplified DNA fragment was cloned into the TA cloning vector pCR1000 (Invitrogen Corp). Sequence analysis of the cloned PCR fragment indicated the presence of two copies of the scnA gene separated by 30 bp (Fig. 2) . The first (5') copy (scnA') differed from scnA by one-nucleotide change but no amino acid changes. The second (3') copy (scnA") was 89% identical to scnA at the nucleotide level and differed by 4 (of 51) amino acids. The four amino acid changes all occurred within the first seven amino acids of the leader peptide. A putative ribosome-binding site is present 5' to both scnA' and scnA". The 30 bp separating the two gene copies was not a duplication of DNA 5' or 3' to the scnA structural gene. DNA 5' to scnA' and 3' to scnA" was similar in sequence to DNA surrounding the scnA gene in strain FF22. To confirm that the sequence obtained after PCR amplification was correct, we determined the sequence of the cloned EcoRI fragment. No differences were observed between the amplified and directly cloned sequences.
Primers used for PCR amplification of the streptococcin A-M49 genes were positioned outside the coding region of the structural gene (Fig. 2) . Therefore, during amplification both copies (scnA ' and scnA") along with the 30 bp between the scn genes were amplified, accounting for the differences in size observed between strain FF22 and the streptococcin-producing M-type 49 strains. If primers were used that amplified only the structural gene of the M-type 49 (10) . The region of DNA which encoded lacticin 481 also contained an open reading frame that was similar to a transposase (9) , although it is not known whether this has a role in lacticin transposition. No evidence for a transposase has been found to date in sequences upstream or downstream of the scn genes in group A streptococci (unpublished data). Complete sequence information of the streptococcin operon may offer insight into the possibility that a transposon is associated with the production of lantibiotics in the group A streptococci.
Nucleotide sequence accession number. The sequence data published here has been submitted to GenBank under accession number L36235.
